Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Decartes-08 · 1 trial · 1 indication
To evaluate the efficacy of Descartes-08 as assessed by the proportion of Myasthenia Gravis Activities of Daily Living (MG-ADL) responders at Month 4.
| Arm | Type | Description |
|---|---|---|
| Decartes-08 | EXPERIMENTAL | This group will undergo leukapheresis and receive manufactured Decartes-08 |
| Placebo | PLACEBO_COMPARATOR | This group will receive placebo |
| Name | Type | Description |
|---|---|---|
| Decartes-08 | BIOLOGICAL | Autologous mRNA CAR T-cell therapy |
| Placebo Drug | OTHER | infusion without Decartes-08 |
Inclusion Criteria: * Patient must be at least 18 years of age. * Patient must have generalized myasthenia gravis (gMG), Myasthenia Gravis Foundation of America (MGFA) clinical classification grades 2-4 at the time of Sscreening. * MG-Activities of Daily Living (MG ADL) total score ≥ 6. * Concomita...